Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis

Journal of Gastroenterology

Volumn 38, Issue 8, 2003, Pages 740-746

  Hibi, Toshifumi ^a   Naganuma, Makoto ^a   Kitahora, Tetsuji ^b   Kinjyo, Fukunori ^c   Shimoyama, Takashi ^d  

^a KEIO UNIVERSITY   (Japan)

^b National Okura Hospital   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Azathioprine; Maintenance of remission; Thiopurine methyltransferase; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; MERCAPTOPURINE; PREDNISONE; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; BONE MARROW SUPPRESSION; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYSTITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FREQUENCY ANALYSIS; HAIR LOSS; HOT FLUSH; HUMAN; JAPAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; AZATHIOPRINE; BONE MARROW DISEASES; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 0141521863     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1139-2     Document Type: Article

References (32)

1. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine. 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
2. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35.
3. Candy S, Wright J, Gerber M, Adams G, Gerig R, Goodman R. A controlled double blind study of azathioprine in the treatment and maintenance of remission in Crohn's disease. Gut 1995;37: 674-8.
4. Ewe K, Press A, Singe C, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
5. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaputopurine: a long-term, randomized, double blind study. N Engl J Med 1980;302:981-7.
6. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
7. Summers RW, Switz DM, Sessions JT, Best WR, Becktel JM, Lenk LF, et al. National Cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-69.
8. Willoughby JM, Beckett J, Kumer PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;II:944-7.
9. O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;II: 955-7.
10. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
11. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon ATR, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
12. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;87:96-9.
13. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-22.
14. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-4.
15. Present DH, Melzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989;111: 641-9.
16. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
17. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117: 809-14.
18. Markowitz J, Grancher K, Mandel F, Daum F. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Am J Gastroenterol 1993;88:44-8.
19. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21.
20. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68-82.
21. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai H, Pui C, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for ozathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
22. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
23. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
24. Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999;38:944-7.
25. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-6.
26. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. BMJ 1974;4:627-30.
27. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. BMJ 1982;284:1291-2.
28. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ 1989;298:82-7.
29. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow up of patients with Crohn's disease treated with azathioprine or 6-mercaputopurine. Lancet 1996;347:215-9.
30. Naganuma M, Hibi T. Do immunosuppressants really work as maintenance therapy after the achievement of remission of severe ulcerative colitis? J Gastroenterol 2002;37:315-31.
31. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated disease: basic and clinical correlates. Ann Intern Med 1993;119:1198-208.
32. D'Haens G, Rutgeerts P. Postoperative recurrence of Crohn's disease: pathophysiology and prevention. Inflamm Bowel Dis 1999;5:295-303.